Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2018.02.001
Abstract: BACKGROUND Treatment with direct-acting antiviral drugs in interferon-free regimens is currently recommended for viral hepatitis C recurrence after liver transplantation. There are limited data regarding its results in this population, and no optimal treatment scheme… read more here.
Keywords: real world; ribavirin; treatment; liver transplant ... See more keywords
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1360313
Abstract: We acknowledge that older data were used in our model, which can be explained by the fact that we finalized the model inputs before the 2014 CDC statistics were published. The updated age and sex… read more here.
Keywords: daclatasvir; daclatasvir sofosbuvir; reply cost; cost effectiveness ... See more keywords
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus–Positive Kidney Transplant Recipients
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000567
Abstract: Background: Limited data exist on the pharmacokinetic profile of novel direct-acting antivirals in kidney transplant recipients. Daclatasvir is primarily eliminated through the biliary route and sofosbuvir through the renal route; here, we report the pharmacokinetic… read more here.
Keywords: egfr min; kidney transplant; transplant recipients; sofosbuvir 331007 ... See more keywords